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The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organized a
2-day international conference on decision making in healthcare in Central and Eastern
Europe with a focus on reimbursement decisions for medicines using health technology
assessment (HTA) [1]. The aim of this conference was to showcase best practice examples in
pricing and reimbursement decision making in Europe and also discuss common challenges
and possible ways to overcome them, present new pharmacoeconomic methodologies and
outcomes research techniques and learn about the latest trends in health economics
modeling. Speakers included international and local experts in pricing and reimbursement
decisions representing different stakeholder groups.
Background
Obtaining value for money and ensuring the
long-term sustainability of healthcare systems is
a priority in all European countries and beyond.
Achieving these objectives becomes even more
important for countries with comparatively less
resources available to spend on healthcare like
Central and Eastern European (CEE) countries.
However, they also face the greatest challenges
in pursuing these objectives due to a number of
factors. Some of these factors are related to the
country’s health and political system and
include limited capacity to introduce economic
principles in health care decision making,
greater impact of political interference and gov-
ernment changes on health care decisions and
governance, dominance of budget imperatives
over cost–effectiveness criteria and developing
healthcare systems. Another important factor
relates to the financial attractiveness of these
markets in terms of size and affordability. The
modest population size and low spending on
health pharmaceuticals in many CEE countries
could result in limited attractiveness of their
markets to pharmaceutical companies launching
new high-cost therapies. The latter, unwilling
to deviate too much from average official prices,
may also be reluctant to offer the same
confidential pricing conditions offered to larger
Western European countries.
Drawing from the wide-ranging experience
of CEE and beyond, a faculty of international
experts in health care decision making pre-
sented examples of instrument for evidence-
based decision making, challenges hampering
their implementation and suggested possible
ways to overcome them.
Health care decision making
Using the example of the Polish Pricing
Authority, Krzysztof Łanda (CEO HTA Audit,
Poland) showed how it is possible to reduce
waiting times by regulating tariffs of health
services. While the regulation of non-drug tar-
iffs remains a challenge in Poland, the
improvement of the drug pricing policy, fol-
lowing the introduction of the Pricing Author-
ity in 2011, enabled e477.8 million and
e215 million savings on drugs in 2012 and
2013, respectively (HTA Audit’s estimations
based on databases from National Health
Fund website). The role of the Polish Eco-
nomic Commission was then compared with
the Australian Independent Hospital Pricing
Authority, which is tasked with setting the
national efficient price for Australian public
hospital services. The national efficient price is
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calculated using a cost model based on cost and activity data
from three previous years. This is then converted into a pricing
model using national weighted activity unit and is a major
determinant of government funding for public hospital services
serving as a benchmark for efficient cost [2].
Mark Parker (Senior Economic Modeler at the University of
Liverpool, UK) provided an overview of health economics-
based instruments that can be used to guide decision making.
These include budget impact analysis (BIA), cost–effectiveness
analysis, multiple criteria decision analysis and value-based pric-
ing. Independent of the instrument used, transparent decision-
making criteria are a necessity, but not sufficient prerequisite
for decisions to be politically acceptable.
Evidence tools in decision making
When considering a technology for reimbursement, cost–effec-
tiveness analysis tells us what the incremental cost for an addi-
tional unit of benefit of the new technology is in comparison
to current available treatments (although the analysis can also
compare two established technologies). However, it does not
tell us what the total cost of treating the eligible patient popu-
lation is. Information on the actual budget impact of accepting
a new drug for reimbursement is crucial because even if a drug
is cost–effective, it may not be affordable without significant
changes in budget allocation. In Poland, BIA is required when
introducing or increasing the price of an innovative or generic
drug. Using concrete examples from her own work, Daria
Szmurlo (Senior Health Economist and Team Leader at HTA
Consulting) showed wide range of applications BIA can have
in supporting decision making. These include forecasting the
reimbursement cost of new technologies, developing risk shar-
ing schemes (RSS), creating therapeutic reference price groups,
negotiating prices and predicting impact of policy changes. BIA
can be conducted from different perspectives, thus becoming a
useful instrument not only for public payers but also for service
providers, pharmaceutical companies and decision makers.
Using Croatia as an example, Vanesa Benkovic (Senior HTA
and Health Research Consultant at Solpharm) discussed some
of the challenges hampering access to innovative drugs in CEE.
These can be ascribed to challenges relating to the decision-
making process, including political interference in resource allo-
cation, predominant role of budget impact consideration, lim-
ited transparency, accountability and capacity to conduct HTA.
In addition, there are also financial challenges including debt
accumulation by healthcare providers, reimbursement delays
and restricted budget available for drugs. This translates into
limited breadth and depth of the benefit package and higher
out-of-pocket spending on individuals. Existing challenges have
been exacerbated by the financial crisis and the need to comply
with the Maastricht criteria of maximum debt levels, heavy reli-
ance on hospital care and an ageing population. In response to
these challenges, health authorities have introduced coping
mechanisms, including long waiting times, limiting reimburse-
ment indications, requiring failure of other treatments before
access is granted, engagement in RSS with the manufacturer
but also simply shifting the financial risk to the individual. The
speaker concluded with calling for partnerships, rather than
competition, between the public sector, the pharmaceutical
industry, patients and professionals as the way forward.
Similar challenges were highlighted to affect access to inno-
vative medicines in Bosnia and Herzegovina (BH) by Tarik
Catic (Founder and President of ISPOR BH). As recognized
by the previous speaker, the impact of these factors is amplified
for orphan drugs. However, while Croatia has a special fund
for expensive drugs including orphan drugs, no special funding
arrangements or RSS are available for orphan drugs in BH.
While not yet implemented, the legal basis for patient registries
is available. Further, recent developments such as the introduc-
tion of e-healthcare IDs in the Canton of Sarajevo, the diabetes
registry led by ISPOR BH and the renal registry of the Society
for Nephrology, Dialysis and Transplantation in Bosnia [3]
could pave the way for their implementation. Registries expan-
sion would create new opportunities to engage in RSS and,
therefore, serve as tool to improve access to patients.
Building on the potential of patient registries, Tanja Nova-
kovic (President of the Pharmacoeconomic Section of the Serbian
Pharmacist Association) discussed the use of big data to support
decision making. The digitization of patient data provides an
unprecedented opportunity to complement data from rando-
mised clinical trials (RCTs) and provide insights into effective-
ness, costs and safety in real life, based on large patient
populations. ‘Big data’ represent a collection of data sets that is
difficult to process with conventional analytical tools (e.g., Excel,
Stata, SPSS, etc.). However, due to their high volume, high
velocity and high variety [4], a number of challenges need to be
addressed. These include storage and analytical capacity as well as
privacy protection before they can be converted into knowledge
that can be used for decision making. Concrete steps have already
been undertaken to address these issues with new storage systems
and analytical software launched in recent years that have enabled
researchers to use these data for analysis [5]. A practical applica-
tion of the use of big data in discrete event simulation [6] for
HTA was explored during a workshop led by Mark Parker.
Clinical data in decision making
Clinical data is key to evidence-based decision making and
there are different ways in which it can be used. In his presen-
tation, Janko Samardzic (Specialist in Clinical Pharmacology at
the Institute of Pharmacology and Toxicology, Serbia) dis-
cussed the role of prescription guidelines in improving rational
prescribing. A survey in 2009 found that in 23 of the 27 EU
Member States, payers had introduced prescription guidelines
and in nine Member States these guidelines were obligatory [7].
The impact of prescription guidelines is greatest when
implemented together with measures such as monitoring
e-prescribing and e-guideline systems, both of which are
expected to be implemented in Serbia soon.
Eldon Spackman (Research Fellow at the University of York,
UK) discussed the use of off-label comparators in HTA based on
the experience of the National Institute for Health and Care
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Excellence (NICE). Although NICE is not able to recommend
use of off-label comparators, their inclusion as a comparator in
HTA is allowed, if justified. Out of 54 single technology
appraisals completed between 2010 and 2012, scopes of
14 appraisals recommended the inclusion of at least one off-label
comparator [8]. Using the example of bevacizumab in England,
the presenter showed how lack of incentive on the man-
ufacturer’s side to apply for a license may result in nonoptimal
outcomes. Bevacizumab, a drug approved for cancer, was found
to be equally effective [9] to ranibizumab for the treatment of wet
age-related macular degeneration; however, because it is not
approved for this indication, NICE could not recommend its
use. It was estimated that the National Health Service could save
GBP 84.5 million annually based on injecting 17,295 eyes each
year by switching from ranibizumab to bevacizumab [10].
Best practices in decision making
This session included an overview of pharmaceutical policies to
manage the introduction of new drugs and improve rational
use, recent changes in HTA systems in Germany and Romania
and options to introduce HTA in Serbia.
In the past years, a number of new drugs have been
launched at very high prices, yet, bringing modest healthcare
gains [11] to the extent that some believe most new drugs and
indications provide minor or similar health improvements to
existing therapies [12]. Using the example of dabigratran [13],
Brian Godman (Senior Researcher at the Karolinska Institute,
Sweden and Professor Strathclyde Institute of Pharmacy and
Biomedicial Sciences, Scotland) presented the model of pre-,
peri- and postlaunch activities [14] to optimize use of new
drugs. The model starts from horizon scanning and goes all the
way to evaluating adherence to guidelines. Further, he pre-
sented evidence of ongoing measures to release valuable resour-
ces from greater use of generics. Examples include the
preference pricing policies in the Netherlands [15], which led to
low prices for generics such as omeprazole; a package of
generic-friendly policies introduced in Lithuania [16] and the
Republic of Srpska [17] showing that good policies rather than
population size are key to achieving low prices for generics;
and a set of demand-side measures encompassing education,
engineering, economics and enforcement (the ‘4Es’) exemplified
by the Wise List in Stockholm [18]. According to the speaker,
continuous cross-countries learning to improve the rational use
of medicines building on examples such as the Wise List in
Stockholm will be essential to sustain progress made toward
universal health coverage.
In 2011, Germany introduced a system of early value assess-
ment (Act on the Reform of the Market for Medical
Products [AMNOG] [19]) moving away from a system of rela-
tive free pricing with volume controls and some statutory
rebates and contractual discounts. While the latter have been
maintained and their absolute value and share of sales have
increased over time, evidence on the added therapeutic benefit
of new drugs, rated on a 1 to 6 scale similar to the French
Ame´lioration du Service Me´dical Rendu/Improvement (ASMR)
system, is now used in pricing negotiations. Examples from the
first 74 assessments conducted under this new system were pre-
sented by York Zo¨llner (Professor of Health Economics at
Hamburg University of Applied Sciences). These suggest that
robust evidence and well-designed trials are rewarded in terms
of price, while for instance the lack of comparator arm, poor
quality RCT design and use of an off-label comparator have
penalized drugs under assessment. Under AMNOG arrange-
ments, drugs with no additional therapeutic benefit are clus-
tered in a reference price group. Currently, 78% of all drugs
on the German market fall under reference pricing.
Alin Liviu Preda (ISPOR Romania) presented the difficult
process of introducing HTA in Romania amid government
changes, involvement of different external advisors [20–22], lack
of consensus among key stakeholders and sudden policy
changes such as recent withdrawal of a previously approved
HTA methodology. This methodology was based on a simple
scorecard system with a 10-point scale and a 6-point threshold
for a positive decision. The scoring system was meant to
account for decisions made by HTA bodies in France and the
UK, the reimbursement status in other EU countries, relative
efficacy/effectiveness, safety and patient-reported outcomes. He
concluded by highlighting the need for a comprehensive
approach to HTA including health financing and the definition
of the basic health care package, a clear and realistic implemen-
tation strategy and a ‘change champion’ in the government
who will engage in this process with a long-term mandate.
Similarly to Romania and other CEE countries, Serbia is try-
ing to strengthen the role of pharmacoeconomics in its
decision-making process for drug reimbursement. To fill the
interim gap while developing national capacity to conduct
HTA, Ruth Lopert (Adjunct Professor, George Washington
University) proposed the introduction of a price benchmarking
system based on the outcome of HTA appraisals in countries
with well-established HTA systems, known prices and appraisals
results. This mechanism assumes a fixed relationship between
cost–effectiveness and gross domestic product per capita, the lat-
ter used as a proxy for affordability. Under this assumption, a
drug is unlikely to be cost–effective if listing is consistent with
the conditions considered cost–effective in the reference country
and the price is higher than the reference country price adjusted
for relative per capita gross domestic product. However, she also
stressed that the result is indicative only, and the process is not
a substitute for properly conducted HTA, but could be applied
as a ‘quick check’ of value-for-money of current (and proposed)
drugs only, and as a guide to price negotiation.
Decision making in Serbia
Dragana Baltezarevic´ (Republic Health Insurance Fund, Serbia)
provided an overview of the pricing and reimbursement process
in Serbia. Assuring quality of generics, improving rational use
of medicines, finding sustainable procurement mechanisms for
essential medicines, controlling costs through increased use of
economic principles in the decision-making process, conducting
more analysis of drug utilization including cross-country
Evidence-based decision making in health care in Central Eastern Europe Meeting Report
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comparisons and more reliable budget impact forecasts that
could be used to conclude volume cap agreements for new
medicines were identified as some of the main challenges and
aspiration currently faced in Serbia. Recent developments like
the introduction of a legal basis to implement RSS and volume
cap schemes provide opportunities to address some of these
issues together with participation in international networks
such as the Pharmaceutical Pricing and Reimbursement Infor-
mation [23] and Piperska [24]. Future priorities for Serbia
include developing a national pharmaceutical policy, the defini-
tion of a high threshold value for innovative medicines, intro-
ducing electronic file submission for reimbursement
applications and central procurement for pharmacies, establish-
ing an HTA unit and building national capacity in economic
evaluation, greater collaboration with other countries on drug
utilization and starting to implement RSS.
While the focus of this conference was on decision making in
the pharmaceutical sector, recent reforms are also trying to
improve provider payment mechanisms. Predrag Djukic (Deliv-
ery of Improved Local Services [DILS] Project, Ministry of
Health, Serbia) discussed current efforts to introduce diagnostic-
related groups for inpatient acute care services in the country.
Their introduction is initially planned for reporting and analyti-
cal purposes with the idea to then gradually move toward their
implementation as a payment mechanism.
Bojan Trkulja (Managing Director of the Innovative Drugs
Manufacturers’ Association, Serbia) called for a switch from a
cost-containment attitude based on price cuts, de-listings, inter-
national reference pricing, generic promotion through INN ten-
dering and substitution, reimbursement restrictions to an
approach based on value-based pricing, risk sharing agreements,
use of health economic evaluation and evidence-based decisions.
Conclusions
Despite the diversity of the countries represented and issues
portrayed, various common themes emerged: the limited num-
ber of new chemical entities accepted for reimbursement in the
CEE, delayed access, cost-shifting to patients and limited fund-
ing for orphan drugs. Beyond the health system itself, health
system governance was recognized as being deeply affected by
political priorities and changes in government.
It was also clear that speakers had diverging opinions on the
value of new medicines with some presenting figures showing
that life expectancy increased at a higher pace between 2000–
2009 in countries where new drugs have been on the market
for more years [25], while others highlighting the modest sur-
vival gains brought by new drugs at very high prices [12]. While
the contribution of new medicines such as antibiotics, vaccines,
insulin and other basic medicines for diabetes and cardiovascu-
lar conditions to population health in the last century is
unquestionable, there is evidence from regulatory and HTA
assessments that survival gains for cancer drugs are mostly very
modest. For example, only 3 of the 12 cancer drugs approved
by the US FDA in 2012 actually prolonged survival and two
of them by less than 2 months [11]. Further, studies looking at
the overall impact of novel medicines on survival should be
interpreted with caution due to methodological challenges in
conducting this type of analyses [26]. Due to differences in
demography, burden of disease, clinical practice, resource use
and unit costs just to name a few, caution is also needed when
transferring results of HTA from one country to another [27–29]
and adjustments need to be made before using results from
other countries to make resource allocation decisions in other
settings [30].
Of course, there are also other important outcomes to
evaluate such as symptomatic improvements, whether a new
drug enables the patient to go back to work and/or signifi-
cantly increases their quality of life. In this respect, HTA
plays a vital role in assessing the additional benefits of new
drugs in comparison to available treatments and comparing
these with their additional costs. However, because medicines
are only one component of disease therapy, to achieve better
health outcomes, it is also essential to strengthen other com-
ponent of the healthcare systems, particularly early diagnosis
and access to quality health care services. Only a strong and
resilient health care system will ultimately be able to deliver
good outcomes for patients, and medicines are only one com-
ponent of it.
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